Marker Therapeutics, Inc.

MUN:GX1 Stock Report

Market Cap: €26.6m

Marker Therapeutics Valuation

Is GX1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GX1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GX1's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GX1's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for GX1?

Key metric: As GX1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GX1. This is calculated by dividing GX1's market cap by their current revenue.
What is GX1's PS Ratio?
PS Ratio5.1x
SalesUS$5.40m
Market CapUS$27.66m

Price to Sales Ratio vs Peers

How does GX1's PS Ratio compare to its peers?

The above table shows the PS ratio for GX1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.1x
MDG1 Medigene
3x16.1%€22.6m
2INV 2invest
8.2xn/a€63.8m
CNW co.don
0.7xn/a€6.5m
HPHA Heidelberg Pharma
12.3x16.6%€103.9m
GX1 Marker Therapeutics
5.1x70.7%€27.7m

Price-To-Sales vs Peers: GX1 is good value based on its Price-To-Sales Ratio (5.1x) compared to the peer average (7.8x).


Price to Sales Ratio vs Industry

How does GX1's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
GX1 5.1xIndustry Avg. 8.1xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: GX1 is good value based on its Price-To-Sales Ratio (5.1x) compared to the European Biotechs industry average (7.9x).


Price to Sales Ratio vs Fair Ratio

What is GX1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GX1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate GX1's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies